

Supplementary Table 2. Univariable and multivariable analyses of baseline clinicopathologic factors for invasive breast cancer-free survival

Variable	Univariable analysis		Multivariable analysis	
	HR (95% CI)	<i>p</i> value	HR (95% CI)	<i>p</i> value
T				
T1a	1		1	
T1b	0.24 (0.05–1.15)	0.074	0.29 (0.06–1.43)	0.129
Operation				
BCS	1			
Mastectomy	1.05 (0.29–3.72)	0.943		
Lymphatic invasion				
None	1			
Present	1.46 (0.18–12.04)	0.725		
Hormone receptor				
Negative	1			
Positive	0.59 (0.15–2.30)	0.451		
Ki67				
≤ 20	1		1	
> 20	2.17 (0.61–7.71)	0.233	2.24 (0.61–8.24)	0.224
Ki67				
≤ 14	1			
> 14	2.34 (0.30–18.47)	0.421		
p53				
Negative	1			
Positive	1.36 (0.38–4.84)	0.633		
RT				
No	1			
Yes	0.57 (0.15–2.21)	0.416		
Chemotherapy				
No	1			
Yes	0.56 (0.16–1.95)	0.363		
Anti-HER2				
No	1			
Yes	0.32 (0.04–2.54)	0.281		
ET				
No	1		1	
Yes	0.19 (0.02–1.52)	0.119	0.29 (0.04–2.31)	0.24
Treatment				
None			1	
Chemotherapy only	0.75 (0.20–2.81)	0.668	1.10 (0.28–4.24)	0.892
Chemotherapy + antiHER2	2.28 (0.03–2.42)	0.247	0.37 (0.04–3.26)	0.372

HR, hazard ratio; CI, confidence interval; BCS, breast-conserving surgery; Ki-67, Ki-67 labeling index; p53, tumor protein p53; RT, radiotherapy; HER2, human epidermal growth factor receptor 2; ET, endocrine therapy.